Daniel J. Weisdorf
About
Daniel J. Weisdorf is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Daniel J. Weisdorf has authored 732 papers receiving a total of 38.4k indexed citations (citations by other indexed papers that have themselves been cited), including 531 papers in Hematology, 192 papers in Oncology and 186 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Daniel J. Weisdorf's work include Hematopoietic Stem Cell Transplantation (466 papers), Acute Lymphoblastic Leukemia research (173 papers) and Acute Myeloid Leukemia Research (159 papers). Daniel J. Weisdorf is often cited by papers focused on Hematopoietic Stem Cell Transplantation (466 papers), Acute Lymphoblastic Leukemia research (173 papers) and Acute Myeloid Leukemia Research (159 papers). Daniel J. Weisdorf collaborates with scholars based in United States, United Kingdom and Canada. Daniel J. Weisdorf's co-authors include Todd E. DeFor, Bruce R. Blazar, Jeffrey S. Miller, John E. Wagner, Clara D. Bloomfield, Hartmut Döhner, Philip B. McGlave, Claudio G. Brunstein, Margaret L. MacMillan and Juliet N. Barker and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.
In The Last Decade
Daniel J. Weisdorf
705 papers receiving 37.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel J. Weisdorf United States | 96 | 24.2k | 13.3k | 11.4k | 6.3k | 5.1k | 732 | 38.4k | ||
| Richard E. Champlin United States | 113 | 27.2k 1.1× | 12.6k 0.9× | 14.9k 1.3× | 7.1k 1.1× | 6.7k 1.3× | 1.1k | 45.3k | ||
| Gèrard Socié France | 91 | 18.7k 0.8× | 9.2k 0.7× | 7.4k 0.6× | 4.9k 0.8× | 3.4k 0.7× | 701 | 30.2k | ||
| Paul J. Martin United States | 98 | 20.5k 0.8× | 12.4k 0.9× | 6.9k 0.6× | 4.9k 0.8× | 3.3k 0.6× | 568 | 34.2k | ||
| Arnon Nagler Israel | 88 | 21.6k 0.9× | 12.6k 0.9× | 12.5k 1.1× | 5.4k 0.9× | 7.8k 1.5× | 1.1k | 39.3k | ||
| Sergio Giralt United States | 86 | 21.4k 0.9× | 7.0k 0.5× | 10.0k 0.9× | 4.9k 0.8× | 5.6k 1.1× | 856 | 30.2k | ||
| Franco Locatelli Italy | 88 | 12.5k 0.5× | 9.9k 0.7× | 8.4k 0.7× | 3.7k 0.6× | 7.6k 1.5× | 1.0k | 33.0k | ||
| Éliane Gluckman France | 93 | 19.2k 0.8× | 7.8k 0.6× | 6.5k 0.6× | 3.6k 0.6× | 4.6k 0.9× | 627 | 29.5k | ||
| H. Joachim Deeg United States | 94 | 23.2k 1.0× | 6.8k 0.5× | 7.1k 0.6× | 5.6k 0.9× | 3.7k 0.7× | 669 | 31.0k | ||
| Stephen J. Forman United States | 100 | 12.3k 0.5× | 9.1k 0.7× | 16.3k 1.4× | 4.8k 0.8× | 8.1k 1.6× | 861 | 36.2k | ||
| Joseph H. Antin United States | 90 | 17.8k 0.7× | 9.5k 0.7× | 6.4k 0.6× | 4.2k 0.7× | 2.7k 0.5× | 491 | 28.0k |
Countries citing papers authored by Daniel J. Weisdorf
Since
Specialization
Citations
This map shows the geographic impact of Daniel J. Weisdorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Weisdorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Weisdorf more than expected).
Fields of papers citing papers by Daniel J. Weisdorf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel J. Weisdorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Weisdorf. The network helps show where Daniel J. Weisdorf may publish in the future.
Co-authorship network of co-authors of Daniel J. Weisdorf
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Weisdorf. A scholar is included among the top collaborators of Daniel J. Weisdorf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Weisdorf. Daniel J. Weisdorf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cao, Qing, Fiona He, Angela Krämer, et al.. (2024). The Prevalence of Pretransplant Frailty and Mental Distress in Hematopoietic Cell Transplantation and Association with Clinical Outcomes. Transplantation and Cellular Therapy. 30(9). 919.e1–919.e9.
2.
Shanley, Ryan, et al.. (2024). Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes. Transplantation and Cellular Therapy. 30(7). 688.e1–688.e9.
3.
Jurdi, Najla El, et al.. (2024). Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy. 30(6). 616–625.
4.
Yan, Chengcheng, Melissa A. Richard, Christopher J. Gibson, et al.. (2024). Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma. Journal of Clinical Oncology. 42(20). 2415–2424.
5.
Saliba, Rima M., Christopher G. Kanakry, Shahinaz M. Gadalla, et al.. (2023). Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. American Journal of Hematology. 99(1). 38–47.
6.
Mehta, Rohtesh S., Jeremy Ramdial, David Marín, et al.. (2023). Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplantation and Cellular Therapy. 29(6). 377.e1–377.e7.
7.
Young, Jo‐Anne H., Najla El Jurdi, Ahmad Rayes, et al.. (2022). Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(8). 509.e1–509.e11.
8.
Kim, Hee‐Je, Daniel J. Weisdorf, & David Gottlieb. (2021). Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy. PubMed. 4(Special Edition). S20–S27.
9.
Bachanová, Veronika, Daniel J. Weisdorf, Tao Wang, et al.. (2018). Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation. 25(5). 949–954.
10.
Hegerova, Livia, Qing Cao, Aleksandr Lazaryan, et al.. (2017). Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplantation. 52(5). 697–703.
11.
Rashidi, Armin, Michael A. Linden, Todd E. DeFor, et al.. (2017). History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease‐negative first complete remission. American Journal of Hematology. 92(10). 1032–1036.
12.
Vallera, Daniel A., Martin Felices, Ron McElmurry, et al.. (2016). IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clinical Cancer Research. 22(14). 3440–3450.
13.
Brunstein, Claudio G., Jeffrey S. Miller, David H. McKenna, et al.. (2015). Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 127(8). 1044–1051.
14.
MacMillan, Margaret L., Todd E. DeFor, Jo‐Anne H. Young, et al.. (2015). Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood. 125(24). 3798–3804.
15.
Levine, John E., Brent R. Logan, Juan Wu, et al.. (2012). Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 119(16). 3854–3860.
16.
Foley, Bree, Sarah Cooley, Michael R. Verneris, et al.. (2011). Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 119(11). 2665–2674.
17.
Sun, Can-Lan, Liton Francisco, K. Scott Baker, et al.. (2011). Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood. 118(17). 4723–4731.
18.
Brunstein, Claudio G., Jonathan A. Gutman, Daniel J. Weisdorf, et al.. (2010). Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 116(22). 4693–4699.
19.
McClune, Brian, Daniel J. Weisdorf, Tanya L. Pedersen, et al.. (2010). Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology. 28(11). 1878–1887.
20.
Brunstein, Claudio G., Juliet N. Barker, Daniel J. Weisdorf, et al.. (2007). Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 110(8). 3064–3070.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Richard E. Champlin Breakdown of academic impact, for papers by Gèrard Socié Breakdown of academic impact, for papers by Paul J. Martin Breakdown of academic impact, for papers by Arnon Nagler Breakdown of academic impact, for papers by Sergio Giralt Breakdown of academic impact, for papers by Franco Locatelli Breakdown of academic impact, for papers by Éliane Gluckman Breakdown of academic impact, for papers by H. Joachim Deeg Breakdown of academic impact, for papers by Stephen J. Forman Breakdown of academic impact, for papers by Joseph H. Antin